EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing Within Approximately 12 Months

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!

  • The most trusted brand in stock market news
  • Fatest intelligence & alerts
  • Active trader chat rooms
  • Option trade alerts
  • Only comprehensive mobile notifications solution
  • Welcoming & white glove support
Posted In: BiotechNewsMarket-Moving ExclusivesExclusivesGeneral